Mass­a­chu­setts is of­ten con­sid­ered the epi­cen­ter of the biotech in­dus­try be­cause of its nu­cle­us of world-class re­search in­sti­tu­tions churn­ing out new sci­en­tists and new star­tups...

Cell ther­a­py man­u­fac­tur­ing start­up Cel­lares is de­fend­ing it­self against Bris­tol My­ers Squibb af­ter the drug­mak­er pulled out of a con­tract claim­ing Cel­lares’ com­mer­cial man­u­fac­tur­ing tech­nol­o­gy...

Bio­haven has found a com­mer­cial part­ner for its late-stage epilep­sy drug.

South Ko­rea-based SK Bio­phar­ma­ceu­ti­cals has of­fered up to $795 mil­lion for the glob­al rights...

The FDA gave the green light to a high­ly an­tic­i­pat­ed pan­cre­at­ic can­cer treat­ment that has al­tered the prospects for pa­tients fac­ing the dead­ly dis­ease.

The...

Ake­so and its part­ner Sum­mit Ther­a­peu­tics pro­claimed on Tues­day that their high-pro­file PD-1xVEGF bis­pe­cif­ic hit a ma­jor Phase 3 mile­stone out­side of lung can­cer.

Ake­so...

Au­ro­ra Ther­a­peu­tics, the first com­pa­ny that fo­cused on cre­at­ing be­spoke gene edit­ing treat­ments, has laid off sev­er­al staff mem­bers and stopped its lead pro­gram.

The...